MS **Prescription Referral Form**

Phone: 1-877-592-7988 Fax: 1-800-787-0874





ate Medication Need 1: Patient I	ded: Ship To: OF	Patient's Home OPreso	criber's Office OPick-up		
		Disthdato	Sex: OMale OFemale Height: Wei	aht.	lbs Ola
Patient Name: Birthdate: Soc. Sec. #: Preferred Phone:				-	_
Address:					
	Name:		Preferred Phone:	z.p	
			ACK copy of ALL Insurance cards (Prescription and Me	dical)	
2: Prescrib	er Information	o iaxi ita ita ana a	terrespy of the moderation of the moderation and mo	areary .	
			DEA#: NPI#:	Tax ID#:	
			Phone: Fax:		
City, State, Zip:			Key Contact: Phone: _	Phone:	
3: Diagnosi	is/Clinical Information	Please FAX recent cli	nical notes, Labs, Tests, with the prescription to expedi	ite the Prior Aut	horizati
	fultiple Sclerosis		Number of relapses in past year:		
Has the patient been previously treated for this condition? OYes ONo			Last MRI date: Any MRI changes? OYes ONo Inection training completed by:		
Prior failed medication (medication and duration of treatment/reason for d/c):					
]			Novantrone:		
	therapy? OYes ONo Medication(s		Is patient's LVEF <50%? OYes ONo		
Will patient be stopi ○Yes ○No	ng above medication before startin Discontinuation Date:		What is lifetime (cumulative) Novantrone dose (mg/m2)? Copy of last CBC with differential:		
	ologist? If no, please include neurolog		Is patient pregnant, nursing or planning pregnancy?	es ONo ON/A	
	Other:		Serum Creatine Creatinine Clearance		
4: Prescrip	tion Information				
Medication	Dose/Strength		Sig	Qty.	Refills
□ Avonex®	□ AVOSTARTGRIP Titration Kit □ 30mcg Prefilled Syringe #4	☐ Dose Titration: • Week 1: Inject 7	7.5mcg IM once weekly		0
		Week 2: Inject 15mcg IM once weekly Week 3: Inject 22.5mcg IM once weekly Week 4+: Inject 30mcg IM once weekly		4 week supply	
	☐ 30mcg Pen #4				
		☐ Inject 30mcg IM on	30mcg IM once weekly		
□ Betaseron®	□ 0.3mg vial	Dose Titration: • Weeks 1-2: Injection	ct 0.0625mg/0.25ml subcutaneously QOD		
		Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD Maintenance Dose: 0.25mg /1ml subcutaneously QOD			0
				4 week supply	
		Other:			
	☐ 20mg Prefiled Syringe	□ 20mg SQ QD		4 wook supply	
☐ Copaxone®	☐ 40mg Prefiled Syringe		week, at least 48 hours apart on the same 3 days each week	4 week supply	
□ Extavia®	□ 0.3mg vial	□ Dose Titration: • Weeks 1-2: Inje	ct 0.0625mg/0.25ml subcutaneously QOD		
		• Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD • Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD • Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD			0
				4 week supply	
☐ Glatopa®	☐ 20mg Prefiled Syringe	□ 20mg SQ QD		4 week supply	
☐ Gilenya®	□ 0.5mg capsule	☐ Take 0.5mg po QD		4 week supply	
*			utaneously three times a week weeks 1-2,	117	
☐ Rebif®	☐ Titration Pack (8.8mcg/22mcg) ☐ 22mcg Prefilled Syringe ☐ 44mcg Prefilled Syringe	22mcg subcutaneously three times a week weeks 3-4, and 44mcg subcutaneously three times a week weeks 5+ (48 hours apart) Maintenance: Inject 22mcg (0.5ml) SQ three times a week (48 hours apart) Maintenance: Inject 44mcg (0.5ml) SQ three times a week (48 hours apart)			0
				4 week supply	
Rebif Redidose®					
		☐ Other:			
Patient Su	upport Programs: Please sign a	nd date below to er	nroll in the pharmaceutical company assisted patient	support prograi	m
tient Signature:			Date:		
	Prescr	iber Signature: Pre	scriber, please sign and date below		
spense as written			Substitution Permissable		
		Date		Date	
	alty Pharmacy and its representatives to act as is intended to be delivered only to the named address			Prescriptions:	